Conversely, the aggressive clinical course in subset no. 2 cases is paralleled by a low-affinity and fast-dissociating BcR IG self-recognition (Table 2), and a steady CLL cell response on receptor crosslinking that reflects a higher reactivity through the BcR35. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.